
    
      Participants with advanced Parkinson's Disease who have been prescribed LCIG for at least 12
      months will be entered into the study cohort. Clinical data will be collected by
      retrospective review of the participant's medical records as well as a single study visit for
      current data. Treatment of the participants and follow up will be according to the
      physician's judgment, regional regulations and the product monograph.
    
  